Lv51
820 积分 2025-12-15 加入
Dual MYC and GSPT1 Protein Degrader for MYC-Driven Hematologic Malignancies
2天前
已完结
Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma
3天前
求助中
Promises and potential pitfalls of in vivo CAR gene therapy
7天前
已完结
Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective Study
7天前
已完结
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
23天前
已完结
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
23天前
已完结
Parallel 4-1BB Signaling in Dual DLL3/CD56-Targeting CAR-T Cells Triggers Adaptive Proliferation and Functional Persistence to Eradicate Small Cell Lung Cancer
24天前
已完结
Target Product Profile and Clinical Development Plan
28天前
已完结
Cytogenetics-based Clinical Trajectories in Patients with MRD Negativity Post Autologous Transplant for Multiple Myeloma
28天前
已完结
GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma
1个月前
已完结
皖公网安备34019202002308
